MAAT INDEX

CLAIM #56596 · Thermo Fisher Scientific Inc (TMO) · 2025Q4 earnings call · Jan 29, 2026 · due Dec 31, 2026

We expect approximately $500 million of net interest expense in 2026.

Stephen Williamson · CFO

CANNOT_DETERMINE
resolved by a revision, graded at the moved level · official band 5 percent
Committed
approximately $500 million of net interest expense in 2026
Reported
approximately $660 million of net interest expense, which now includes financing for the Clario acquisition

How to check this claim

Look at: Net interest expense, fiscal year 2026

It came true if: Full-year 2026 net interest expense between $475 million and $525 million

Where: Company income statement / 10-K (FY2026 annual report)

In context

peed and scale to minimize them and provide our usual level of transparency as to their impact. The guidance includes $600 million of inorganic revenue from the acquisitions closed in 2025. In that inorganic period, these acquisitions are expected to contribute $60 million of adjusted operating income. The math of which adds a 20 basis point headwind to adjusted operating margins in 2026. After factoring in the financing costs, they represented 7¢ of adjusted EPS dilution for 2026. These acquisitions are progressing well versus our deal model expectations. We're in the integration and investment phase in 2026, which is setting us up to deliver strong accretion and very attractive returns going forward. To help you with your modeling, here are a few additional assumptions behind the guide. We expect approximately $500 million of net interest expense in 2026. We assume that the adjusted income tax rate will be 11.5% in 2026, largely driven by the increased earnings. We're expecting between 1.8% and $2 billion of net capital expenditures in 2026. The increase over '25 is driven by our investments in US manufacturing. In terms of free cash flow, we're expecting that to be in the range of $6.8 billion to $7.3 billion for the year. In terms of capital deployment, we're assuming $3 billion of share buybacks which were already completed in January. We estimate a full-year average diluted share count will be between 370 and 375 million shares. I'm assuming we'll return approximately $700 million of capital to shareholders this year through dividends. And finally, I wanted to touch on phasing for Q1. Embedded in the guidance is the assumption that Q1

Verify independently

SEC filings for TMO · Claim quote is verbatim from the 2025Q4 earnings call.